Relenza outperforms Tamiflu in bird flu study

The antiviral Relenza has won a battle over Tamiflu in the competition for government contracts from governments anxious about a possible bird flu epidemic. New research published in Nature demonstrates that Relenza is better than Tamiflu in guarding against H5N1. In the test, patients infected with the H5N1 virus demonstrated resistance to Tamiflu but were helped by Relenza, which is made by GlaxoSmithKline. And analysts saw the results as a sign that governments around the world could start buying large quantities of Relenza as one line of defense against a human pandemic.

"Antiviral medicines are a key component of any flu pandemic response plan and the Nature article further highlights the important role of zanamivir (Relenza) in preparing for a future pandemic," said GSK Pharmaceuticals Europe president Eddie Gray.

- read the article from The Age

ALSO: Indonesian officials still stubbornly refuse to turn over samples of new bird flu strains unless it is guaranteed access to any new vaccines that are developed from it. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.